{"slug":"gene-editing-therapies","topic":"gene-editing-therapies","title":"CRISPR & Gene-Editing Therapies: State of the Field (October 2026)","summary":"Covers CRISPR-Cas9 nuclease therapies, base and prime editors, the delivery systems that decide which tissues can be edited, and the safety questions that dominate current debate. The most important takeaway: the first approved CRISPR therapy is an ex vivo product for hemoglobinopathies, while in vivo, bespoke and prime-editing programs remain mostly in early or pivotal trials with unresolved long-term safety.","version":1,"published_at":"2026-10-30","updated_at":"2026-10-30","stats":{"words":3638,"citations":52,"claims":27,"timeline":18,"benchmarks":6,"open_problems":7,"key_papers":14,"glossary":15},"verification":{"status":"verified","method":"automated figure and citation-relevance triage against cited abstracts, plus targeted AI review with web checks of flagged statements; automated citation resolution","claims_checked":34,"issues_fixed":10,"verified_at":"2026-10-30"},"ai_assisted":true,"price":{"usd":"0.20","protocol":"x402","network":"eip155:84532","asset":"USDC"},"url":"https://space-kitty.com/dossiers/gene-editing-therapies","preview_url":"https://space-kitty.com/api/v1/dossiers/gene-editing-therapies/preview","purchase_url":"https://space-kitty.com/api/v1/dossiers/gene-editing-therapies","toc":[{"level":2,"text":"Executive summary","anchor":"executive-summary"},{"level":2,"text":"Background and core concepts","anchor":"background-and-core-concepts"},{"level":2,"text":"Timeline of key milestones","anchor":"timeline-of-key-milestones"},{"level":2,"text":"State of the art","anchor":"state-of-the-art"},{"level":3,"text":"Ex vivo nuclease editing: exa-cel","anchor":"ex-vivo-nuclease-editing-exa-cel"},{"level":3,"text":"In vivo LNP-delivered editing","anchor":"in-vivo-lnp-delivered-editing"},{"level":3,"text":"Base editing","anchor":"base-editing"},{"level":3,"text":"Prime editing","anchor":"prime-editing"},{"level":3,"text":"Edited immune cells","anchor":"edited-immune-cells"},{"level":3,"text":"Quantitative benchmarks","anchor":"quantitative-benchmarks"},{"level":2,"text":"Open problems and active debates","anchor":"open-problems-and-active-debates"},{"level":2,"text":"Major programs and players","anchor":"major-programs-and-players"},{"level":2,"text":"Outlook: what to watch (next 12-18 months)","anchor":"outlook-what-to-watch-next-12-18-months"},{"level":2,"text":"Key papers","anchor":"key-papers"},{"level":2,"text":"Glossary","anchor":"glossary"}],"sample_claims":["CRISPR-Cas systems are prokaryotic adaptive immune systems whose guide-programmed nucleases were repurposed as genome-editing tools.","Base editors and prime editors modify DNA without the double-strand break that Cas9 nuclease editing relies on."],"includes":["markdown","claims","timeline","benchmarks","open_problems","key_papers","glossary","bibliography"],"citation_count":52,"how_to_buy":"GET https://space-kitty.com/api/v1/dossiers/gene-editing-therapies with an x402 client ($0.20, USDC on Base Sepolia (testnet))."}